UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 9, 2018
PIERIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
Nevada | 001-37471 | EIN 30-0784346 | ||
(State of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
255 State Street, 9th Floor
Boston, MA 02109
United States
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: 857-246-8998
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company ý
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01: Regulation FD Disclosure.
On November 9, 2018, Pieris Pharmaceuticals, Inc. presented preclinical data regarding PRS-344. The poster is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
The information set forth under this “Item 7.01. Regulation FD Disclosure,” including the exhibits attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PIERIS PHARMACEUTICALS, INC. | ||
Dated: November 9, 2018 | /s/ Allan Reine | |
Allan Reine | ||
Chief Financial Officer | ||
Simultaneous costimulatory T-cell engagement and checkpoint inhibition by PRS-344/ONC0055, a 4-1BB / PD-L1 bispecific compound for tumor localized activation of the immune system Marina Pavlidou*1, Janet Peper*1, Lucia Pattarini*2, Christian Barthels1, Eva-Maria Hansbauer1, Rachida Bel Aiba1, Milan Blanusa1, Alix Scholer-Dahirel2, Maximilien Grandclaudon2, Céline Grand2, Jamila Elhmouzi-Younes2, Matthieu Rivière2, Véronique Blanc2, Christine Rothe1, Shane Olwill1 1Pieris Pharmaceuticals GmbH, Lise-Meitner-Straße 30, 85354 Freising, Germany 2Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France *Co-authors / equally contributing authors PRS-344/ONC0055 is capable of robust target PRS-344/ONC0055 demonstrates synergistic effect PRS-344/ONC0055 induces an effective CD8 T cell Background engagement in T cell activation response in a mixed lymphocyte reaction The combination of atezolizumab and anti-4-1BB benchmark PRS-344/ONC0055 induces an effective CD8 T cell response in Multiple lines of evidence show that 4-1BB (CD137), a key PRS-344/ONC0055 bispecific demonstrates comparable target demonstrates the strong synergistic effect of T cell co- MLR shown by secretion of several cytokines and cytotoxic costimulatory immunoreceptor, is a highly promising binding properties to 4-1BB and PD-L1 as the respective single building blocks and is capable to bind both targets stimulation and checkpoint blockade in T cell activation. With molecules which is superior to combination of benchmarks. therapeutic target in cancer. Current antibody-based simultaneously. PRS-344/ONC0055, this synergistic effect is massively C approaches showed immune cell activation not only in tumor D u a l b in d in g increased. A 4 -1 B B b in d in g IL -2 G r a n z y m e A 3 0 0 0 0 tissues but also in the periphery, associated with dose-limiting 3 0 0 0 0 8 0 0 1 5 0 0 0 ] l m / g ] 6 0 0 on-target toxicity and a limited therapeutic window. To l 2 0 0 0 0 T c e ll a c tiv a tio n in S E B a s s a y p [ 1 0 0 0 0 m 2 0 0 0 0 6 0 0 0 / A g U p F e U 4 0 0 overcome this limitation, we generated PRS-344/ONC055, a [ F R m 2 R - y z ® 1 0 0 0 0 L 5 0 0 0 5 0 0 0 I 4-1BB/PD-L1 bispecific Anticalin /antibody fusion protein. 1 0 0 0 0 2 0 0 n a P R S -3 4 4 /O N C 0 0 5 5 r P R S -3 4 4 /O N C 0 0 5 5 G PRS-344/ONC055 is designed to promote 4-1BB clustering on a n ti-4 -1 B B A n tic a lin ] 4 0 0 0 0 0 0 l e 4 b b B 5 e 4 b b B 5 0 l a 5 l a 5 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0 1 0 0 0 m ic G A B 0 ic G A B 0 / g g 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0 1 0 0 0 h I m m -1 0 h I m m 1 0 4-1BB-positive T cells only in presence of PD-L1 expressing u u - e h 4 C e h 4 C C o n c e n tra tio n [n M ] g V iz B i- V iz B i- l B t N l t N o B C o n c e n tra tio n [n M ] p 1 n O o 1 n O 3 0 0 0 z - a / z - / [ a e 4 4 e 4 4 t - + 4 t - + 4 a ti i -3 a t 3 cells. PD-L1, the primary ligand of the T-cell receptor PD-1, is 2 b b - n a S n a B Figure 2. PRS-344/ONC0055 target binding. - a a S m R m R P D -L 1 b in d in g L u P u P I z z li li 2 0 0 0 o o widely expressed in the tumor microenvironment resulting in 3 0 0 0 0 A) Direct binding to human 4-1BB was tested z z e t te by coating 4-1BB on a plate and detecting the a a an inhibitory interaction with PD-1. Combining 4-1BB-induced 1 0 0 0 P e r fo r in G r a n z y m e B 2 0 0 0 0 binding of the molecules via anti-Anticalin- T-cell co-stimulation and expansion with anti-PD-L1 mediated 1 0 0 0 0 4 0 0 0 U ] scaffold. B) Direct binding to human PD-L1 l F 0 ] R m 2 5 2 5 2 5 2 5 2 5 2 5 2 5 5 2 4 8 1 2 6 1 3 5 1 2 4 8 6 1 3 5 8 1 3 5 1 2 1 2 4 4 8 6 1 3 5 1 2 4 8 6 1 1 2 4 8 6 3 5 1 3 5 1 2 4 1 3 5 1 2 4 8 6 1 3 5 8 6 6 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 l / . . . . . . . . 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 6 2 0 0 0 0 0 0 0 1 3 6 2 0 0 0 0 1 3 6 2 0 0 0 0 1 3 6 2 0 0 0 0 1 3 6 2 0 0 0 0 1 3 6 2 0 0 0 0 1 3 6 2 0 0 0 0 1 3 6 2 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2 2 2 2 2 2 2 g 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 m 3 0 0 0 . . . . . . . . . . . . . . . . 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 immune checkpoint blockade may overcome the limitation of was tested by coating human PD-L1 on a plate 0 1 0 0 0 0 / p 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 [ g p 6 0 0 0 B P R S -3 4 4 /O N C 0 0 5 5 [ and detecting the molecules via anti-hIgG. C) C o n c e n tr a tio n [n M ] e single agent therapy and offer benefit to ICP-resistant or non- n 2 0 0 0 i a n ti-P D -L 1 b u ild in g b lo c k r 4 0 0 0 m Simultaneous binding of PRS-344 was tested o y 0 P R S -3 4 4 /O N C 0 0 5 5 a te z o liz u m a b f z r n responsive patients. PRS-344/ONC0055 not only merges the 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0 1 0 0 0 a te z o liz u m a b + a n ti-4 -1 B B m A b e 1 0 0 0 a by coating human PD-L1 on a plate and a n ti-P D -L 1 b u ild in g b lo c k P 2 0 0 0 C o n c e n tra tio n [n M ] r potential of a combinatorial therapy in one molecule but also detecting PRS-344 via biotin-labeled human 4- a n ti-4 -1 B B m A b F c -4 -1 B B -a n tic a lin fu s io n G a n ti-P D -L 1 b u ild in g b lo c k + a n ti-4 -1 B B m A b h Ig G 4 0 0 e 4 b b B 5 e 4 b b B 5 l a 5 l a 5 1BB. ic G A B 0 ic G A B 0 g m 1 g m 1 favors the localized activation of antigen-specific T cells in the h I m - 0 h I m - 0 e h u 4 C e h u 4 C V iz B i- V iz B i- l B t N l B t N o 1 n O o 1 n O z - a / z - a / e 4 4 e 4 4 t i- + 4 t i- + 4 tumor microenvironment, potentially reducing peripheral a t 3 a t 3 n b - n b - a a S a a S PRS-344/ONC0055 recognizes functional relevant Figure 6. PBMCs from healthy blood donors were stimulated with 0.1 ng/ml SEB in m R m R u P u P z z li li toxicity. o o presence of various concentrations of constructs. After 3 days, IL-2 secretion levels z z te te Here we provide a preclinical dataset demonstrating that PRS- epitopes were measured from the supernatant. Exemplary data is shown. Background IL-2 a a 344/ONC0055 is capable of providing strong 4-1BB-mediated PRS-344/ONC0055 bispecific effectively competes with PD-1 levels was 35 pg/ml (PBMC + SEB without constructs). No increase in IL-2 secretion Figure 8. CD8 T cells were co-cultured for 6 days with mature monocyte-derived observed when PBMC were not activated with SEB (not shown). T-cell co-stimulation that is strictly PD-L1 dependent and /PD-L1 binding and shares an overlapping 4-1BB binding dendritic cells from another healthy blood donor. Cytokine secretion was measured from the supernatant. Results are shown for IL-2, Granzyme A, Granzyme B and requires simultaneous TCR signaling thereby restricting T cell epitope with clinically active anti-4-1BB benchmark mAb. B Perforin. Similar results were obtained for IFNγ, TNFα, GM-CSF, IL-13, IL-5, soluble activation to antigen-specific, tumor-localized T cells. PRS- A PRS-344/ONC0055-mediated T cell activation is PD- FasL, MIP-1α and MIP-1β. No change in secretion levels observed for IL-6. Graphs C o m p e titio n w ith a n ti-4 -1 B B b e n c h m a rk show results of 4 different donors. C o m p e titio n w ith P D -1 /P D -L 1 b in d in g 344/ONC0055 provides good target binding properties and to 4 -1 B B b in d in g L1 dependent and only occurs in combination with pharmacokinetics supporting further development of this drug. 2 0 1 .2 TCR activation ] ] 1 .0 PRS-344/ONC0055 displays antibody-like M 1 5 M This program is part of the strategic alliance between Pieris n n [ [ 0 .8 r r PRS-344/ONC0055-mediated co-stimulation is strictly PD-L1 pharmacokinetics in mice e e and Servier. c 1 0 c 0 .6 a a r r dependent, reducing the risk of peripheral toxicity. In addition, t t 0 .4 e e The mab-like half-life of the anti-PD-L1 mAb building block is e 5 e co-stimulation only occurs in combination with simultaneous r r f Concept: Tumor-localized co-stimulatory T cell f 0 .2 preserved within PRS-344/ONC0055. TCR signaling, further restricting PRS-344/ONC0055-mediated activation combined with checkpoint blockade 0 0 .0 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0 1 0 0 0 0 .0 0 1 0 .0 1 0 .1 1 1 0 1 0 0 1 0 0 0 co-stimulation to antigen-specific T cells. C o n c e n tra tio n [n M ] C o n c e n tra tio n [n M ] PRS-344/ONC0055 clusters 4-1BB only in the presence of PD- P R S -3 4 4 /O N C 0 0 5 5 P R S -3 4 4 /O N C 0 0 5 5 A P D -L 1 b u ild in g b lo c k C o -c u ltu r e w ith P D -L 1 p o s itiv e c e lls high a n ti-P D -L 1 b u ild in g b lo c k L1 expressing tumor and/or antigen-presenting cells in the a te z o liz u m a b a n ti-4 -1 B B m A b tumor microenvironment or tumor-draining lymph node. At the 1 2 0 0 0 Figure 3. A) Competition to PD-1/PD-L1 binding was assessed in an ELISA based Construct t1/2 [h] P R S -3 4 4 /O N C 0 0 5 5 same time, blocking the PD-1/PD-L1 interaction further increases 1 0 0 0 0 format using coated human PD-1 and human PD-L1-Fc as a tracer. Detection was a n ti-P D -L 1 b u ild in g b lo c k Anti-PD-L1 building 390 a n ti-4 -1 B B m A b block T cell responsiveness. However, no clustering of 4-1BB is performed with anti-hIgG. B) Competition with an anti-4-1BB benchmark mAb was ] 8 0 0 0 L a te z o liz u m a b + a n ti-4 -1 B B m A b assessed in an ELISA based format using coated anti-4-1BB benchmark mAb and m PRS-344/ONC0055 295 expected in the periphery where PD-L1 expression levels are / h Ig G 4 human 4-1BB-biotin as a tracer. Detection was performed via ExtrAvidin-HRP. g 6 0 0 0 p low. [ 2 No T cell co-stimulation - L in periphery PRS-344/ONC0055-mediated costimulation is I 4 0 0 0 2 0 0 0 highly effective and PD-L1 dependent b a c k g ro u n d 0 3 8 3 3 8 3 3 8 3 3 8 3 3 3 8 7 7 7 7 7 7 7 7 7 7 9 2 6 6 2 6 9 6 2 6 9 6 2 6 9 6 2 6 9 6 0 0 0 0 0 . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 2 0 0 0 0 2 2 2 0 0 2 0 0 0 0 0 0 0 5 5 5 5 5 6 . 6 . . . 6 6 . 6 0 1 5 0 0 1 5 0 0 1 5 0 0 1 5 0 0 1 5 4-1BB clustering and downstream signaling mediated by PRS- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 . . . . . . . . . . . . . . . 1 0 1 0 1 0 1 0 1 T cell 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 344/ONC0055 in presence of a PD-L1-positive cell line are 0 Figure 9. PK was analyzed in male CD1 mice of about 6 weeks of age. Animals were C o n s tru c t [n M ] significantly stronger than those of the benchmark anti-4-1BB injected with 10 mg/kg of the respective construct and plasma samples taken at the 4-1BB mAb and are strictly PD-L1 dependent indicated timepoints. ADA-positive samples were removed and a non-compartmental analysis performed. No 4-1BB B C o -c u ltu r e w ith P D -L 1 n e g a tiv e c e lls clustering PRS-344/ h igh h igh T cell co-stimulation in the ONC0055 + co-stimulation A w ith P D -L 1 ta rg e t c e lls B w ith o u t P D -L 1 ta rg e t c e lls 1 2 0 0 0 tumor microenvironment 6 0 6 0 P R S -3 4 4 /O N C 0 0 5 5 P R S -3 4 4 /O N C 0 0 5 5 1 0 0 0 0 a n ti-P D -L 1 b u ild in g b lo c k d d n Low PD-L1 n Conclusion 5 0 5 0 a n ti-P D -L 1 b u ild in g b lo c k a n ti-4 -1 B B m A b u u o o r r expression a n ti-4 -1 B B m A b ] g g 8 0 0 0 a te z o liz u m a b + a n ti-4 -1 B B m A b L k 4 0 k 4 0 c Tumor-specific c a te z o liz u m a b + a n ti-4 -1 B B m A b a a m h Ig G 4 / b b h Ig G 4 r r T cell g e e 6 0 0 0 p v 3 0 v 3 0 [ o Healthy cell o n n 2 o o • PRS-344/ONC0055 is a 4-1BB/PD-L1 bispecific based - i i t 2 0 t 2 0 L c c I 4 0 0 0 u u d d n n on the genetic fusion of a high-affinity 4-1BB-binding i i 1 0 1 0 d d l l o 4-1BB clustering + o ® f f 2 0 0 0 Anticalin moiety and an anti-PD-L1 mAb. T cell co- + 0 0 b a c k g ro u n d stimulation Blocking checkpoint function 0 .0 1 0 .1 1 1 0 0 .0 1 0 .1 1 1 0 0 • Target binding is retained in the bispecific format and 3 8 3 3 8 3 3 8 3 3 3 8 3 3 8 7 7 7 7 7 7 7 7 7 7 9 2 6 6 2 6 9 6 2 6 9 2 6 6 6 2 6 9 6 9 0 0 0 0 C o n c e n tr a tio n [n M ] 0 . . . . . . . . . . . . . . . . . . . . . . . . C o n c e n tr a tio n [n M ] . 0 0 2 0 0 0 0 2 2 2 0 0 0 0 2 0 0 0 0 0 5 5 5 5 5 6 . 6 . . . 6 6 . 6 0 0 1 5 0 0 1 5 0 0 1 5 0 0 1 5 0 0 1 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 . . . . . . . . . . . . . . . 0 1 0 1 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 both arms of the PRS-344 bispecific are functional. Figure 4. PRS-344/ONC0055-mediated co-stimulatory activity was measured in a Tumor- C o n s tru c t [n M ] High PD-L1 specific T cell Jurkat-4-1BB-NF-κB reporter cell line. A) in presence or B) absence of PD-L1-positive • PRS-344/ONC0055-mediated 4-1BB activation is strictly expression colon cancer cell line RKO. C PD-L1 dependent potentially reducing the risk of C o -c u ltu r e w ith P D -L 1 p o s itiv e c e lls peripheral toxicity. Furthermore, 4-1BB co-stimulation Blocking PRS-344/ONC0055 bispecific retains full 1 2 0 0 0 Tumor cell / APC only occurs in combination with simultaneous TCR PD-1 PD-1/PD-L1 checkpoint blockade capacity P R S -3 4 4 /O N C 0 0 5 5 interaction 1 0 0 0 0 a n ti-P D -L 1 b u ild in g b lo c k signaling further reducing the risk of peripheral toxicity a n ti-4 -1 B B m A b PRS-344/ONC0055 retains checkpoint blockade activity similar ] 8 0 0 0 by limiting co-stimulation to antigen-specific T cells. L a te z o liz u m a b + a n ti-4 -1 B B m A b m High PD-L1 / to anti-PD-L1 mAb building block and atezolizumab h Ig G 4 g 6 0 0 0 • PRS-344/ONC0055 induces an effective CD8 T cell expression p [ P D -1 /P D -L 1 b lo c k a d e 2 - response by secretion of several cytokines and L 5 .0 I 4 0 0 0 P R S -3 4 4 /O N C 0 0 5 5 d cytotoxic molecules. n 4 .5 u a n ti-P D -L 1 b u ild in g b lo c k o r a te z o liz u m a b 2 0 0 0 g 4 .0 Tumor cell / APC k b a c k g ro u n d • PRS-344/ONC0055 demonstrates strong synergistic c h Ig G 4 a b 3 .5 r 0 e v 0 0 0 0 0 effect in T cell activation which is more pronounced o 5 5 5 5 3 .0 5 n Figure 1. Concept of tumor-localized co-stimulatory T cell activation combined with o i t 2 .5 C o n s tru c t [n M ] than the combination of benchmarks. c immune checkpoint blockade. A) Low PD-L1 expression in the periphery is not able u d n 2 .0 i d to sufficiently cluster 4-1BB which is required to ensure 4-1BB signaling. This results l • In mice, PRS-344/ONC0055 displays antibody-like o f Figure 7. Pan T cells from healthy blood donors were co-cultured in 0.25 µg/ml anti- in a reduced risk of peripheral toxicity. B) High PD-L1 expression in the tumor 1 .5 1 .0 CD3 mAb coated plates in presence of various concentrations of constructs with A) pharmacokinetics. microenvironment, presented on tumor cell and/or APCs, leads to sufficient 4-1BB 0 .0 1 0 .1 1 1 0 1 0 0 PD-L1 transfected CHO cells or B) mock transfected CHO cells. C) 50 nM of each C o n c e n tr a tio n [n M ] clustering resulting in a tumor-localized T cell co-stimulation, further enhancing TCR construct were added to Pan T cells co-cultured with PD-L1 transfected CHO cells in The here-reported preclinical data support proceeding to signaling of tumor-specific T cells. C) At the same time, the co-inhibitory PD-1/PD-L1 Figure 5. PD-1/PD-L1 checkpoint blockade activity was assessed in a Jurkat-PD-1- absence of anti-CD3 mAb which is activating TCR signaling. Background = Pan T further development of PRS-344/ONC0055. pathway is efficiently blocked, abrogating suppression of tumor-specific T cells. NFAT reporter cell line co-cultured with PD-L1 expressing CHO cells. cells + anti-CD3 mAb + target cell line.